Journal article
A real world multicenter study of first (1L) and second (2L) line treatment patterns and outcomes in advanced pancreatic cancer (APC).
Abstract
476
Background: FOLFIRINOX (FFX), gemcitabine plus nab-paclitaxel (GN), and gemcitabine (gem) are 3 publicly funded and available treatment options for locally advanced (LAPC) and metastatic pancreatic cancer (MPC) in Canada since 2014. Without head-to-head trials that directly compare all 3 regimens, treatment selection and outcomes in 1L and 2L remain poorly characterized in routine clinical practice. Methods: Data from 4 …
Authors
Cheung WY; Zhang H; Tang PA; Spratlin JL; Lee-Ying RM; Goodwin RA; Meyers BM; Armstrong DE; Ramjeesingh R; Vickers MM
Journal
Journal of Clinical Oncology, Vol. 36, No. 4_suppl, pp. 476–476
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2018
DOI
10.1200/jco.2018.36.4_suppl.476
ISSN
0732-183X